Osimertinib Plus Chemo Approved for EGFR-mutated NSCLC Osimertinib Plus Chemo Approved for EGFR-mutated NSCLC
With the new approval, patients now have the option of combination treatment or osimertinib monotherapy.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 22, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news

Perceived vs Actual Cognitive Impairment in Prostate Cancer Perceived vs Actual Cognitive Impairment in Prostate Cancer
Following hormone therapy, patients with prostate cancer may perceive an increase in cognitive issues, despite tests showing no objective decline, a recent meta-analysis found.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 22, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news

Is MRI Screening Unnecessarily High in Prostate Cancer? Is MRI Screening Unnecessarily High in Prostate Cancer?
New research suggests that review of current prostate cancer screening guidelines may be needed, as MRI frequently fails to detect cancer-indicative lesions, even in men with elevated PSA levels.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 21, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news

This Could Be a Strong Weapon for Cancer Pain (or Any Pain) This Could Be a Strong Weapon for Cancer Pain (or Any Pain)
New study on exercise and cancer-related pain adds to mounting evidence that physical activity can help manage pain for a range of conditions.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 21, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news

Open Medical Institute: Physicians Improving Patient Care Open Medical Institute: Physicians Improving Patient Care
Dr Mark Kris discusses the benefits of the Open Medical Institute programs for young physicians.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 20, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

Oxford Analyses: We Need to Ask About Data Availability Oxford Analyses: We Need to Ask About Data Availability
Kathy Miller discusses the importance of collaboration, participation, and data availability for future Oxford analyses.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 16, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

A Protocol for Vaccinating Patients With Lynch Syndrome A Protocol for Vaccinating Patients With Lynch Syndrome
Dr David Kerr discusses a new protocol for treating patients with Lynch syndrome.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 16, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

Should CRC Surveillance Extend Beyond 5 Years Post Surgery? Should CRC Surveillance Extend Beyond 5 Years Post Surgery?
The incidence of late recurrence and metachronous CRC remain low and have decreased over time, limiting the benefit of prolonged CRC-specific surveillance.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 16, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news

Should CRC Surveillance Extend Beyond 5 Years Post-Surgery? Should CRC Surveillance Extend Beyond 5 Years Post-Surgery?
The incidence of late recurrence and metachronous CRC remain low and have decreased over time, limiting the benefit of prolonged CRC-specific surveillance.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 16, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news

Gilead Sciences Pauses Enrollment for Cancer Treatment in Solid Tumor Trials Gilead Sciences Pauses Enrollment for Cancer Treatment in Solid Tumor Trials
Gilead Sciences said on Thursday enrollments to test its cancer drug, magrolimab, on solid tumors had been paused globally, a week after the U.S. regulator put some studies...Reuters Health Information (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 15, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news

CAR T Cell: Do Benefits Still Outweigh Risks? CAR T Cell: Do Benefits Still Outweigh Risks?
Despite concerns about the development of secondary T-cell malignancies due to CAR T-cell immunotherapy, experts still believed that the benefits outweigh the risks.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 15, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news

Include Neoadjuvant Chemotherapy in Stage II-III Lung Cancer Include Neoadjuvant Chemotherapy in Stage II-III Lung Cancer
Mark Kris, MD, discusses the use of a checkpoint inhibitor and chemotherapy as neoadjuvant therapy for every patient with stage II and III lung cancer at the time of diagnosis.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 14, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

Plant-Based Diet a Boon for Men With Prostate Cancer Plant-Based Diet a Boon for Men With Prostate Cancer
New data showed men who eat more fruits and vegetables enjoyed better quality of life, including sexual function.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 14, 2024 Category: Cancer & Oncology Tags: Urology Source Type: news

Frontline Irinotecan Liposome OKed in Mets Pancreatic Cancer Frontline Irinotecan Liposome OKed in Mets Pancreatic Cancer
The approval was based on improved overall and PFS with irinotecan liposome alongside oxaliplatin, fluorouracil, and leucovorin vs gemcitabine plus nab-paclitaxel.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 14, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news

Add-On Fruquintinib Delays Progression in Gastric Cancer Add-On Fruquintinib Delays Progression in Gastric Cancer
Fruquintinib plus paclitaxel improves cancer progression-free, but not overall survival, in patients with gastric/gastroesophageal cancer who have progressed on frontline chemotherapy.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 12, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news